hypertrophic cardiomyopathy
Conditions
Interventions
Group 1: percutaneous endocardial ventricular septal radiofrequency ablation in the treatment of obstructive hypertrophic cardiomyopathy guided by three-dimensional intracardiac echocardiography
Sponsors
Zhongshan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Obstructive hypertrophic cardiomyopathy (echocardiography indicated LVOTG>=50mmHg, resting or loading state), with or without SAM sign; (2) Aged >=18 years old; (3) With or without clinical symptoms (including fatigue, shortness of breath, exertional angina, syncope, etc.), poor efficacy of adequate drug therapy or intolerance to adverse drug reactions; (4) The informed consent and voluntary participation of patients and their families are in accordance with GCP regulations.
Exclusion criteria
Exclusion criteria: (1) Simple apical hypertrophic cardiomyopathy; (2) Non-obstructive hypertrophic cardiomyopathy; (3) LVOTG<50 mmHg (rest or load); (4) Surgical contraindications: including abnormal coagulation function, contraindications for anticoagulation, pregnant and lactating women; (5) Left ventricular ejection fraction < 40%; (6) Life expectancy < 12 months; (7) Patients who are allergic to anesthetic drugs and cannot tolerate surgery; (8) Complications of other heart diseases and require surgical treatment; (9) Poor patient compliance, unable to complete the test requirements; (10) Patients who were considered unfit to participate in this study by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eft ventricular outflow tract gradient,LVOTG;Adverse events; | — |
Countries
China
Contacts
Public ContactWenqing Zhu
Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed